Apellis Pharmaceuticals Inc
1APLS
Company Profile
Business description
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Contact
100 Fifth Avenue
WalthamMA02451
USAT: +1 617 977-5700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
733
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,263.87 | 355.13 | 4.49% |
| DAX 40 | 24,080.63 | 1,159.04 | 5.06% |
| Dow JONES (US) | 47,709.27 | 1,124.81 | 2.41% |
| FTSE 100 | 10,608.88 | 260.09 | 2.51% |
| HKSE | 25,893.02 | 776.49 | 3.09% |
| NASDAQ | 22,549.41 | 531.56 | 2.41% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,757.56 | 140.71 | 2.13% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |